The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab

Shu-Dong Zhang, Cian M. McCrudden, Meng Chen, Yao Lin, Hang Fai Kwok

    Research output: Contribution to journalArticle

    5 Citations (Scopus)
    LanguageEnglish
    Pages835
    JournalOncoTargets and Therapy
    Volume8
    DOIs
    Publication statusPublished - 2015

    Keywords

    • colon cancer
    • VEGFA
    • FLT1
    • KDR
    • angiogenesis
    • survival

    Cite this

    @article{86495642565243bb8e33545bc43e322d,
    title = "The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab",
    keywords = "colon cancer, VEGFA, FLT1, KDR, angiogenesis, survival",
    author = "Shu-Dong Zhang and McCrudden, {Cian M.} and Meng Chen and Yao Lin and Kwok, {Hang Fai}",
    year = "2015",
    doi = "10.2147/OTT.S80518",
    language = "English",
    volume = "8",
    pages = "835",
    journal = "OncoTargets and Therapy",
    issn = "1178-6930",
    publisher = "Dove Medical Press",

    }

    The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab. / Zhang, Shu-Dong; McCrudden, Cian M.; Chen, Meng; Lin, Yao; Kwok, Hang Fai.

    In: OncoTargets and Therapy, Vol. 8, 2015, p. 835.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab

    AU - Zhang, Shu-Dong

    AU - McCrudden, Cian M.

    AU - Chen, Meng

    AU - Lin, Yao

    AU - Kwok, Hang Fai

    PY - 2015

    Y1 - 2015

    KW - colon cancer

    KW - VEGFA

    KW - FLT1

    KW - KDR

    KW - angiogenesis

    KW - survival

    U2 - 10.2147/OTT.S80518

    DO - 10.2147/OTT.S80518

    M3 - Article

    VL - 8

    SP - 835

    JO - OncoTargets and Therapy

    T2 - OncoTargets and Therapy

    JF - OncoTargets and Therapy

    SN - 1178-6930

    ER -